Ezra M. Friedberg, serving as a Director at Pelthos Therapeutics Inc. (NASDAQ: PTHS), executed a sale of 283 shares of the company's common stock on June 15, 2026. The transaction, which was processed through multiple trades, resulted in a total value of $7,724. The per-share prices for these transactions ranged from $27.1245 to $27.9403.
The sale was conducted pursuant to a Rule 10b5-1 trading plan that Friedberg adopted on December 16, 2025. The primary purpose of this plan is to satisfy estimated tax obligations that arise from the vesting of restricted stock units granted to him by the issuer. Following this transaction, Friedberg's direct holdings in Pelthos Therapeutics common stock stand at 81,600 shares. Furthermore, he maintains indirect beneficial ownership through two entities: 82,072 shares held by Balmoral Financial Group LLC and 40,000 shares held by Key Recovery Group LLC. Friedberg acts as the manager for both entities and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
At the time of the transaction, the stock was trading at $27.01. Over the preceding year, the stock has delivered a 125% return, according to InvestingPro data. However, the stock exhibits high volatility, characterized by a beta of 3.2. Analysis from InvestingPro suggests that the stock appears undervalued at current levels relative to its Fair Value estimate.
These insider transactions occur against the backdrop of Pelthos Therapeutics' recent financial reporting. The company reported its Q1 2026 earnings, which revealed a significant miss on earnings per share (EPS) expectations. The company posted an EPS of -3.09 USD, falling short of the forecasted -0.51 USD. This discrepancy marks a surprise of -505.88%.
Despite this substantial earnings miss, the stock experienced an increase in pre-market trading. This movement indicates investor confidence, possibly driven by strong revenue growth and product performance. Additionally, notable insider activity includes a substantial stock purchase by director Todd C. Davis. Davis acquired 35,948 shares of Pelthos Therapeutics' common stock for approximately $999,980. These purchases were executed at weighted average prices ranging from $27.8046 to $28.7261 per share.
The combination of director sales, director purchases, and mixed earnings signals highlights significant investor activity and interest in Pelthos Therapeutics. The company's stock closed at 27.01, down 1.010 (-3.60%) at 15:59:59 USD. In after-hours trading at 16:10:05, the stock rose to 27.01, up 0.160 (+0.60%).